# CASI pharmaceuticals, Inc. clinical trials: 24 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with CASI pharmaceuticals, Inc. as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by CASI pharmaceuticals, Inc.: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/casi-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946549 | A Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia | CASI pharmaceuticals, Inc. | Phase 2 | Not yet recruiting | Chronic Immune Thrombocytopenia | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946549) |
| June 11, 2026 | NCT07641426 | A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated... | CASI pharmaceuticals, Inc. | Phase 1/2 | Recruiting | Antibody Mediated Rejection | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641426) |
| June 12, 2025 | NCT07017725 | A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune... | CASI pharmaceuticals, Inc. | Phase 1/2 | Recruiting | Chronic Immune Thrombocytopenia | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07017725) |
| February 17, 2021 | NCT04758767 | CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma | CASI pharmaceuticals, Inc. | Phase 1 | Completed | Multiple Myeloma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04758767) |
| September 9, 2014 | NCT02234986 | A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02234986) |
| July 12, 2012 | NCT01639248 | Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Triple Negative Breast Cancer | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01639248) |
| April 15, 2010 | NCT01104675 | Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Ovarian Cancer, Fallopian Cancer, Peritoneal Cancer | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01104675) |
| May 20, 2009 | NCT00904787 | Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies | CASI pharmaceuticals, Inc. | Phase 1 | Completed | Relapsed or Refractory Hematological Malignancies | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00904787) |
| December 10, 2008 | NCT00806065 | Study of ENMD-2076 in Patients With Multiple Myeloma | CASI pharmaceuticals, Inc. | Phase 1 | Completed | Multiple Myeloma | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00806065) |
| April 15, 2008 | NCT00658671 | A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer | CASI pharmaceuticals, Inc. | Phase 1 | Completed | Advanced Cancer | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00658671) |
| April 11, 2008 | NCT00656461 | Phase 1 Study of MKC-1 in Patients With Advanced Cancer | CASI pharmaceuticals, Inc. | Phase 1 | Completed | Advanced Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00656461) |
| February 6, 2008 | NCT00607607 | A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Ovarian Cancer, Endometrial Cancer | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00607607) |
| January 14, 2008 | NCT00592579 | A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Relapsed Multiple Myeloma, Plateau Phase Multiple Myeloma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00592579) |
| December 6, 2007 | NCT00568646 | Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Pancreatic Cancer | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00568646) |
| July 25, 2007 | NCT00506402 | A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies | CASI pharmaceuticals, Inc. | Phase 1 | Completed | Hematological Malignancies, Myelodysplasia, Agnogenic Myeloid Metaplasia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00506402) |
| June 1, 2007 | NCT00481455 | Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent... | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Recurrent Glioblastoma Multiforme | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00481455) |
| March 7, 2007 | NCT00444314 | Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Metastatic Renal Cell Carcinoma | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00444314) |
| December 6, 2006 | NCT00408226 | Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer | CASI pharmaceuticals, Inc. | Phase 1/2 | Completed | Advanced Cancer, Non-Small Cell Lung Cancer | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00408226) |
| November 16, 2006 | NCT00400348 | Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Ovarian Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00400348) |
| November 1, 2006 | NCT00394810 | Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Prostate Cancer | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00394810) |
| May 22, 2006 | NCT00328497 | A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Carcinoid Tumor | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00328497) |
| March 24, 2006 | NCT00306631 | A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1 | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Breast Cancer | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00306631) |
| March 24, 2006 | NCT00306618 | Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Recurrent Glioblastoma Multiforme | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00306618) |
| November 15, 2002 | NCT00049790 | Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung... | CASI pharmaceuticals, Inc. | Phase 2 | Completed | Carcinoma, Non-Small-Cell Lung | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00049790) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 1/2 | 3 |
| Phase 2 | 15 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 21 |
| Recruiting | 2 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Myeloma | 3 |
| Ovarian Neoplasms | 3 |
| Breast Neoplasms | 2 |
| Glioblastoma | 2 |
| Hematologic Neoplasms | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Pancreatic Neoplasms | 1 |
| Recurrence | 1 |
| Leukemia | 1 |
| Carcinoma, Renal Cell | 1 |
| Prostatic Neoplasms | 1 |
| Purpura | 1 |
| Carcinoid Tumor | 1 |
| Endometrial Neoplasms | 1 |
| Anemia, Refractory, with Excess of Blasts | 1 |
| Primary Myelofibrosis | 1 |
| Triple Negative Breast Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Psychiatry practices in the United States](https://specstream.ai/data/businesses/psychiatry-practices/united-states)
- [Web design firms in the United States](https://specstream.ai/data/businesses/web-design-firms/united-states)
- [Carpet cleaning companies in the United States](https://specstream.ai/data/businesses/carpet-cleaning-companies/united-states)
- [Foundation repair contractors in the United States](https://specstream.ai/data/businesses/foundation-repair-contractors/united-states)
